The New Weight Loss Drug That Makes Ozempic Look Like the Beginning

In this video, I’m breaking down the most exciting
drug in metabolic medicine right now —retatrutide,
Eli Lilly’s investigational triple agonist that just
reported Phase 3 results that stopped me in my tracks.

As a double board-certified endocrinologist, I’ve
been following this drug closely — and the TRIUMPH-1 and TRANSCEND data are unlike anything I’ve seen in this class.

📊 WHAT THE DATA SHOWS:
▸ 70 lbs lost (28.3% body weight) at 80 weeks on
the highest dose
▸ Up to 30% weight loss at 2 years in severe obesity
▸ 65% of patients dropped below a BMI of 30
▸ A1c reductions of up to 2.0% in Type 2 diabetes
▸ 46% of diabetic patients achieved a completely
normal A1c

💊 WHAT MAKES RETATRUTIDE DIFFERENT:
Semaglutide (Ozempic, Wegovy) activates 1 receptor.
Tirzepatide (Mounjaro, Zepbound) activates 2.
Retatrutide activates 3 — GLP-1, GIP, AND glucagon —
making it the most potent agent ever studied in this class.

⚠️ IMPORTANT: Retatrutide is not yet FDA approved.
A regulatory submission is anticipated in 2026.
This video is for educational purposes only and does
not constitute medical advice.

─────────────────────────────────────────
🔔 SUBSCRIBE for weekly science-backed updates on
hormones, metabolism, GLP-1 medications, and
perimenopause health from a practicing endocrinologist.
─────────────────────────────────────────

─────────────────────────────────────────
👩‍⚕️ ABOUT DR. ALESSIA ROEHNELT
Double board-certified in Endocrinology and Internal
Medicine. Practicing at EndoHealth MD in Westfield, NJ
with telehealth across NJ, NY, and FL.

📍 endohealthmedical.com
📱 Instagram & TikTok: @endohealthdoc
─────────────────────────────────────────

CHAPTERS:
0:00 Hook — The drug changing everything
0:15 What is retatrutide?
0:30 How it differs from semaglutide & tirzepatide
1:00 TRIUMPH-1 Phase 3 weight loss results
1:45 TRANSCEND — A1c and diabetes data
2:30 Who this drug may be for
3:00 When to expect FDA approval

─────────────────────────────────────────
DISCLAIMER: This video is intended for educational
purposes only and does not constitute medical advice.
Always consult a licensed healthcare provider before
starting, stopping, or adjusting any medication.

#retatrutide #GLP1 #weightloss #Ozempic #tirzepatide
#semaglutide #Mounjaro #Wegovy #metabolichealth
#endocrinology #obesity #type2diabetes #hormonehealth
#perimenopause #insulinresistance #endohealthdoc

Share on: